CN104768944B - 2‑吡啶酮化合物 - Google Patents

2‑吡啶酮化合物 Download PDF

Info

Publication number
CN104768944B
CN104768944B CN201380059272.2A CN201380059272A CN104768944B CN 104768944 B CN104768944 B CN 104768944B CN 201380059272 A CN201380059272 A CN 201380059272A CN 104768944 B CN104768944 B CN 104768944B
Authority
CN
China
Prior art keywords
compound
medicine
cyclopropyl
phenyl
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380059272.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104768944A (zh
Inventor
黑田翔
黑田翔一
今井佑大
河口尚则
伏木启子
坊野匡宏
浅沼肇
长南具通
佐藤长明
门马壮
门马壮一
笹子滋正
水谷茉莉衣
伊藤晋
冈田匠
太田博史
石山圣志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of CN104768944A publication Critical patent/CN104768944A/zh
Application granted granted Critical
Publication of CN104768944B publication Critical patent/CN104768944B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201380059272.2A 2012-11-13 2013-11-12 2‑吡啶酮化合物 Expired - Fee Related CN104768944B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012249792 2012-11-13
JP2012-249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 ２－ピリドン化合物

Publications (2)

Publication Number Publication Date
CN104768944A CN104768944A (zh) 2015-07-08
CN104768944B true CN104768944B (zh) 2017-03-29

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380059272.2A Expired - Fee Related CN104768944B (zh) 2012-11-13 2013-11-12 2‑吡啶酮化合物

Country Status (25)

Country Link
US (1) US9695148B2 (enExample)
EP (1) EP2921489B1 (enExample)
JP (1) JP5963025B2 (enExample)
KR (1) KR102160841B1 (enExample)
CN (1) CN104768944B (enExample)
AU (1) AU2013345930B2 (enExample)
BR (1) BR112015010823A2 (enExample)
CA (1) CA2891406C (enExample)
DK (1) DK2921489T3 (enExample)
ES (1) ES2641469T3 (enExample)
HU (1) HUE034557T2 (enExample)
IL (1) IL238701B (enExample)
IN (1) IN2015DN03869A (enExample)
MX (1) MX361479B (enExample)
MY (1) MY173812A (enExample)
NO (1) NO2921489T3 (enExample)
NZ (1) NZ707832A (enExample)
PH (1) PH12015501056A1 (enExample)
PL (1) PL2921489T3 (enExample)
PT (1) PT2921489T (enExample)
RU (1) RU2662157C2 (enExample)
SG (1) SG11201503716RA (enExample)
TW (1) TWI591064B (enExample)
WO (1) WO2014077235A1 (enExample)
ZA (1) ZA201503323B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 ２−ピリドン化合物を含有する医薬
EP3144305A4 (en) * 2014-05-13 2017-12-27 Nissan Chemical Industries, Ltd. Method for producing 2-pyridone compound
JP7265276B2 (ja) * 2018-05-31 2023-04-26 華領医薬技術（上海）有限公司 グルコキナーゼ活性化剤およびｓｇｌｔ－２阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011068211A1 (ja) * 2009-12-04 2011-06-09 大正製薬株式会社 ２－ピリドン化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
CN101466691B (zh) 2006-06-08 2011-07-27 伊莱利利公司 作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US7928230B2 (en) * 2007-07-17 2011-04-19 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
JP2013010750A (ja) * 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd ２−ピリドン化合物を含有する医薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011068211A1 (ja) * 2009-12-04 2011-06-09 大正製薬株式会社 ２－ピリドン化合物

Also Published As

Publication number Publication date
AU2013345930A1 (en) 2015-06-04
SG11201503716RA (en) 2015-06-29
JPWO2014077235A1 (ja) 2017-01-05
EP2921489B1 (en) 2017-09-06
WO2014077235A1 (ja) 2014-05-22
PL2921489T3 (pl) 2018-01-31
CA2891406C (en) 2021-03-16
TWI591064B (zh) 2017-07-11
BR112015010823A2 (pt) 2017-07-11
EP2921489A1 (en) 2015-09-23
IN2015DN03869A (enExample) 2015-10-02
MX2015005884A (es) 2015-12-09
AU2013345930B2 (en) 2017-08-24
RU2015122717A (ru) 2017-01-10
CA2891406A1 (en) 2014-05-22
PH12015501056B1 (en) 2015-07-27
EP2921489A4 (en) 2016-04-06
TW201434826A (zh) 2014-09-16
ES2641469T3 (es) 2017-11-10
ZA201503323B (en) 2016-08-31
JP5963025B2 (ja) 2016-08-03
US20160289208A1 (en) 2016-10-06
RU2662157C2 (ru) 2018-07-24
PH12015501056A1 (en) 2015-07-27
IL238701A0 (en) 2015-06-30
NZ707832A (en) 2019-03-29
KR102160841B1 (ko) 2020-09-28
US9695148B2 (en) 2017-07-04
MY173812A (en) 2020-02-24
DK2921489T3 (en) 2017-10-16
HK1207856A1 (en) 2016-02-12
NO2921489T3 (enExample) 2018-02-03
KR20150082301A (ko) 2015-07-15
MX361479B (es) 2018-12-06
CN104768944A (zh) 2015-07-08
HUE034557T2 (en) 2018-02-28
IL238701B (en) 2018-10-31
PT2921489T (pt) 2017-12-01

Similar Documents

Publication Publication Date Title
EP4563199A2 (en) Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
JP5324427B2 (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
CN104822680B (zh) 咪唑并吡啶化合物
US8481731B2 (en) Compounds, pharmaceutical composition and methods relating thereto
US20230312557A1 (en) P2x3 modulators
TW200942239A (en) Phenylacetamide derivatives
JP2012512849A (ja) スピロインドリノンピリジン誘導体
US12156874B2 (en) Inhibitors of TRPC6
CN104768944B (zh) 2‑吡啶酮化合物
US10975091B2 (en) Pyridine derivative
JP6048533B2 (ja) ２−ピリドン化合物を含有する医薬
TW202340185A (zh) Ampk活化劑
HK1207856B (en) 2-pyridone compound
WO2016088864A1 (ja) ピリジン誘導体
US8569289B2 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151027

Address after: Tokyo, Japan

Applicant after: NISSAN CHEMICAL INDUSTRIES, Ltd.

Address before: Tokyo, Japan

Applicant before: TAISHO PHARMACEUTICAL Co.,Ltd.

Applicant before: NISSAN CHEMICAL INDUSTRIES, Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207856

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1207856

Country of ref document: HK

CP01 Change in the name or title of a patent holder

Address after: Tokyo, Japan

Patentee after: NISSAN CHEMICAL INDUSTRIES, Ltd.

Address before: Tokyo, Japan

Patentee before: NISSAN CHEMICAL INDUSTRIES, Ltd.

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170329

Termination date: 20211112

CF01 Termination of patent right due to non-payment of annual fee